Evidence map›Paper›PMID 30810966›Full record

ArticleJournal of mammary gland biology and neoplasia2019

A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials.

Zsófia Pénzváltó, Jane Qian Chen, Clifford G Tepper, Ryan R Davis, Matthew T Silvestrini, Maxine Umeh-Garcia, Colleen Sweeney, Alexander D Borowsky

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of mammary gland biology and neoplasia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Mouse Tumor Models for Advanced Cancer Immunotherapy.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zsófia PénzváltóCenter for Comparative Medicine, University of California at Davis, Davis, CA, USA.
Jane Qian ChenCenter for Comparative Medicine, University of California at Davis, Davis, CA, USA.
Clifford G TepperDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California at Davis, Sacramento, CA, USA.
Ryan R DavisDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California at Davis, Sacramento, CA, USA.
Matthew T SilvestriniDepartment of Biomedical Engineering, University of California at Davis, Sacramento, CA, USA.
Maxine Umeh-GarciaDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California at Davis, Sacramento, CA, USA.
Colleen SweeneyDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California at Davis, Sacramento, CA, USA.
Alexander D BorowskyCenter for Comparative Medicine, University of California at Davis, Davis, CA, USA. adborowsky@ucdavis.edu.
University of California, Davis · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
UC Davis MCB T32 Administrative Supplement to Recognize Excellence in Diversity, Equity, Inclusion, and Accessibility (DEIA) MentorshipT32GM007377 · NIGMS · UNIVERSITY OF CALIFORNIA DAVIS · PI CHEDIN, FREDERIC LOUIS · 1985 to 2023
$9.9M
Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancersU01CA196406 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOROWSKY, ALEXANDER D, ESSERMAN, LAURA J · 2015 to 2020
$5.8M
The Center for Translational Genomic PhenotypingU01CA141582 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARDIFF, ROBERT D, CHERRY, SIMON R · 2009 to 2013
$3.5M
NCI NIH HHS P30 CA093373NCI NIH HHS U01 CA141582NCI NIH HHS U01 CA196406NIGMS NIH HHS T32 GM007377
6 · The paper itself

Abstract

In order to develop a practical model of breast cancer, with in vitro and syngeneic, immune-intact, in vivo growth capacity, we established a primary cell line derived from a mammary carcinoma in the transgenic FVB/N-Tg(MMTV-ErbB2*)NDL2-5Mul mouse, referred to as "NDL

Indexed as

AnimalsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBreast NeoplasmsCarcinomaCell Line, TumorDrug Screening Assays, AntitumorErb-b2 Receptor Tyrosine KinasesFeasibility StudiesFemaleHumansMammary Neoplasms, ExperimentalMiceMice, TransgenicPrimary Cell CultureAntineoplastic Agents, ImmunologicalB7-H1 AntigenCd274 protein, mouseErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesBreast cancerErbb2ImmunotherapyMouse modelPD-L1Syngeneic

Identifiers

PMID30810966
PMCPMC6612594
OpenAlexW2919026742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.